China’s 2009 Regulatory Changes Will Affect Makers of Drugs, APIs and Devices
This article was originally published in PharmAsia News
Executive Summary
BEIJING - An array of regulatory and legal changes covering pharmaceuticals and medical devices in China is likely to be launched or broadened this year, including new GMP guidelines, as the country aims to upgrade supervision of the entire health care sector, according to a leading Chinese lawyer in the area of life sciences-related issues and legislation
You may also be interested in...
Chinese Drug Regulators Issue New Rules To Increase Safety Standards Of Vaccines
BEIJING - In the wake of a series of vaccine scandals across China during the past year, triggering sometimes fatal adverse events, China's State FDA is strengthening rules governing the manufacturing, distribution and inspection of vaccines nationwide
Chinese Drug Regulators Issue New Rules To Increase Safety Standards Of Vaccines
BEIJING - In the wake of a series of vaccine scandals across China during the past year, triggering sometimes fatal adverse events, China's State FDA is strengthening rules governing the manufacturing, distribution and inspection of vaccines nationwide
U.S. FDA China Country Head Chris Hickey On FDA's Mission In China: An Interview With PharmAsia News (Part 2 of 2)
U.S.FDA established offices in China in 2008 to improve oversight of products exported to the U.S., and to establish stronger working relationships with China's State FDA. The mission of the office initially was to implement two export agreements signed with China in December 2007 to enhance regulatory cooperation in the areas of food, drugs, medical devices and animal feed. PharmAsia News' China and Australia bureaus spoke to FDA China Country Director Christopher Hickey about the mission of the China office and progress being made in China. This is part two of a two-part interview; part one appeared in a recent issue of PharmAsia News.